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Abstract: MASP-2, mannose-binding protein-associated serine protease 2, is a key enzyme in the
lectin pathway of complement activation. Hyperactivation of this protein by human coronaviruses
SARS-CoV, MERS-CoV and SARS-CoV-2 has been found to contribute to aberrant complement
activation in patients, leading to aggravated lung injury with potentially fatal consequences. This
hyperactivation is triggered in the lungs through a conserved, direct interaction between MASP-2
and coronavirus nucleocapsid (N) proteins. Blocking this interaction with monoclonal antibodies and
interfering directly with the catalytic activity of MASP-2, have been found to alleviate coronavirus-
induced lung injury both in vitro and in vivo. In this study, a virtual library of 8736 licensed drugs
and clinical agents has been screened in silico according to two parallel strategies. The first strategy
aims at identifying direct inhibitors of MASP-2 catalytic activity, while the second strategy focusses
on finding protein-protein interaction inhibitors (PPIs) of MASP-2 and coronaviral N proteins. Such
agents could represent promising support treatment options to prevent lung injury and reduce
mortality rates of infections caused by both present and future-emerging coronaviruses. Forty-six
drug repurposing candidates were purchased and, for the ones selected as potential direct inhibitors
of MASP-2, a preliminary in vitro assay was conducted to assess their interference with the lectin
pathway of complement activation. Some of the tested agents displayed a dose-response inhibitory
activity of the lectin pathway, potentially providing the basis for a viable support strategy to prevent
the severe complications of coronavirus infections.
Keywords: MASP-2; coronaviruses; molecular modelling; drug repurposing
1. Introduction
The complement system is crucial for the activation of innate and adaptive immune
responses, and it plays a key role in host defense mechanisms against pathogens [1].
However, its dysregulation can lead to inflammation and its aberrant activation aggravates
several lung-injury disorders [2]. Complement may be activated through the alternative, the
classical and the mannose-binding lectin (MBL) pathways. Among the three pathways of
complement activation, the MBL pathway is the major player to induce a proinflammatory
response in viral infections [3]. Highly pathogenic human viruses such as HIV (human
immunodeficiency virus), SARS-CoV (severe acquired respiratory syndrome coronavirus)
and Ebola virus, all directly interact with components of the MBL pathway [1], with
the dysregulation of the complement system playing main roles in the pathogenesis of
respiratory disorders such as acute lung injury. Acute lung injury represents the more
severe form of several viral diseases, including SARS, MERS (middle east respiratory
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syndrome) and COVID-19 [4,5]. Pharmacological inhibition, using known inhibitors of
complement convertases C3 and C5, which are common factors to the three pathways, has
already been explored as a potential therapy for SARS-CoV-2 infections with encouraging
results [6].
A conserved feature of human coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2,
which is not shared by less pathogenic coronaviruses [7], is their ability to induce an exces-
sive immune response in the host through aberrant activation of the complement system.
This results in aggravated inflammation in the lungs and leads to severe pneumonia and
lung injury, responsible for the high mortality rates of these viral infections [7]. Recent evi-
dence suggests that these highly pathogenic coronaviruses trigger inflammation processes
through a conserved interaction between the viral nucleocapsid (N) protein and the host
MASP-2 serine protease, a key protein in the MBL pathway of complement activation. This
interaction leads to excessive immune responses in the lungs, with severe consequences.
This finding indicated that N protein is not only essential for the virus transcription and
assembly [8] but also plays a key role in the viral pathogenesis of coronaviruses, at least
partially through the interaction and the consequent exacerbated activation of MASP-2.
This hypothesis was further corroborated by the observation that MASP-2 knockout mice
with induced severe pneumonia, which was boosted by SARS-CoV or MERS N protein,
resulted in a higher survival rate and reduced lung damage compared to wild-type mice [7].
The viral N protein portion responsible for this interaction was recently identified, corre-
sponding to residues 115-123 in SARS-CoV-2 (GTGPEAGLP) [7]. While the amino acid
sequence for this portion is highly conserved in SARS-CoV, MERS-CoV and SARS-CoV-2,
sequence alignment revealed significant variations in the corresponding sequence of the N
proteins of other coronaviruses associated with mild diseases, such as human coronaviruses
229E, OC43, NL63, and HKU1 (Figure 1) [9].
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Figure 1. (a) Sequence alignment of the interacting portion of the C-terminal domain of human coronavirus N proteins. 
The region interacting with mannose-binding protein-associated serine protease 2 (MASP-2) is highlighted with a red box. 
While the amino acid composition of this region is highly conserved in highly pathogenic human coronaviruses, signifi-
cant differences are found in the corresponding region of human coronaviruses associated with mild diseases, exemplified 
by 229E-CoV (varying portion highlighted in orange). This sequence variation has been proven to abrogate the ability to 
interact with MASP-2 and induce aberrant complement activation [7]. (b) Sequence alignment between the relevant por-
tion of the C-terminal domain of the SARS-CoV-2 N protein and the corresponding portion of the N proteins of human 
coronaviruses associated with mild diseases [9]. The region interacting with MASP-2, highlighted with a red box, shows 
significant differences (varying portion highlighted in orange). N protein sequences were downloaded from UniProt [10]. 
Sequence alignments were performed with Clustal Omega [11]. In the sequence alignment, ‘*’ indicates conserved resi-
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The region interacting with mannose-binding protein-associated serine protease 2 (MASP-2) is highlighted with a red box.
While the amino acid composition of this region is highly conserved in highly pathogenic human coronaviruses, significant
differences are found in the corresponding region of human coronaviruses associated with mild diseases, exemplified
by 229E-CoV (varying portion highlighted in orange). This sequence variation has been proven to abrogate the ability
to interact with MASP-2 and induce aberrant complement activation [7]. (b) Sequence alignment between the relevant
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Sequence alignments were performed with Clustal Omega [11]. In the sequence alignment, ‘*’ indicates conserved residues,
‘:’ indicates conserved substitutions, while ‘.’ indicates semi-conserved substitutions. Red indicates small and hydrophobic
residues, blue indicates acidic residues, magenta indicates basic residues, green indicates residues containing hydroxyl or
sulfhydryl or amine and G [11].
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Remarkably, the N proteins of different bat coronaviruses not yet known to infect
humans are characterized by the presence of this conserved sequence, as highlighted
in Figure 2, suggesting the potential risk for emergence of new coronavirus zoonotic
infections in the future, with the same serious consequences of SARS-CoV, MERS-CoV and
SARS-CoV-2.
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Both blocking the interaction between MASP-2 and coronavirus N proteins with anti-
N or anti- ASP-2 monoclonal antibodies [7] and interfering directly with the catalytic
activity of MASP-2, have been found to significantly alleviate coronavirus-induced lung
injury both in vitro and in vivo [7,12], suggesting the interference with MASP-2 hyperacti-
vation may be an effective therapeutic approach to reduce lung injury and fatality rates in
coronaviral diseases.
In this study we screened in silico a drug-repurposing library of 8.736 agents that
have been licensed or at least reached clinical trials, according to two parallel strategies,
both aimed at identifying potential modulators of MASP-2 hyperactivation. With the
first strategy, we selected potential direct inhibitors of MASP-2 at its catalytic site and
evaluated them in an in vitro assay for their ability to interfere with the MBL pathway of
complement activation. With the second strategy, we used molecular modelling analyses
to investigate the interaction between MASP-2 and coronavirus N proteins. These studies
allowed the refinement of a plausible structural model for the interaction between these two
proteins, which we used to perform a second in silico screening of our drug repurposing
library. Effective inhibitors of this interaction would enable the selective modulation
of virus-induced immune responses, as opposed to the nonspecific effects of currently
explored treatment options targeting host immune and inflammatory pathways, such as
IL-6 antibodies and steroids [13,14].
2. Materials and Methods
2.1. Molecular Modelling
All molecular modelling experiments were performed on Asus WS X299 PRO Intel®
i9-10980XE CPU @ 3.00GHz x 36 running Ubuntu 18.04 (graphic card: GeForce RTX 2080 Ti)
(Asus, Taipei, Taiwan). Molecular Operating Environment (MOE, 2019.10, Montreal, QC,
Canada) [15], Maestro (Schrödinger Release 2020-2, New York, NY, USA) [16], PLANTS [17],
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Seesar (version 9.2, containing FlexX, Sankt Augustin, Germany) [18] and OpenEye (OE-
Docking 4.0.0.0, containing ScorePose) [19] were used as molecular modelling software. A
virtual library of drug repurposing compounds was built in sdf (structure-data file) format
by combining molecules downloaded from two different database collections containing
FDA-approved drugs, clinical trial drugs, and preclinical tool compounds (DrugBank;
Drug Repurposing Hub) [20,21], and then prepared using the Maestro LigPrep tool by
energy minimizing the structures (OPLS_2005 force filed), generating possible ionization
states at pH 7 ± 2 (Epik), generating tautomers and generating, at most, three low-energy
ring conformers. All the compounds featuring chiral centers were purchased as pure
enantiomers, unless otherwise indicated, in case the drug/chemical agent was used as a
racemic mixture. Configurations at chiral centers were retained as per input structures.
2.1.1. Docking-Based Virtual Screening on MASP-2 Catalytic Site
The virtual library of drug-repurposing compounds was screened on the catalytic site
of the active form of wild-type MASP-2 (i.e., searching for direct inhibitors of MASP-2 ac-
tivity) using the 1Q3X crystal structure (downloaded from the protein data bank PDB) [22].
This structure was prepared using the protein preparation tools in MOE 2019.10, and a
reference ligand was added in the catalytic site using the coordinates of a co-crystallised,
specific MASP-2 peptide inhibitor taken from the 3TVJ crystal structure [23]. Only the
central portion of the ligand directly binding to the MASP-2 catalytic site was kept (centred
on Lys30) and used to define the centre for the docking grid in Maestro. The resulting
protein–ligand complex was saved in three different formats: pdb (to be used for FlexX
and ScorePose rescore), mol2 (to be used for PLANTS rescore after removing the peptide
ligand) and mae (to be used in Maestro to perform the docking study and XP rescoring).
The protein in the mae format was pre-processed in Maestro using the Schrödinger
Protein Preparation Wizard tool, by assigning bond orders, adding hydrogens and per-
forming a restrained energy minimisation of the added hydrogens using the OPLS_2005
force field. A 15 Å docking grid (inner-box 12 Å and outer-box 27 Å) was prepared us-
ing as the centroid the added ligand. The drug-repurposing library was docked on the
active site using the Glide SP (standard precision) docking algorithm [16], keeping the
default parameters, setting to five the number of output poses per input ligand to include
in the solution, and performing a post-docking minimisation of each of the poses kept.
The docking results obtained were then rescored using Glide XP, FlexX Score, CHEMPLP
(PLANTS) and Chemgauss4 (ScorePose) scoring functions [16–19]. The values of the four
different scoring functions for each docking pose were then combined together (consensus
score) and only the docking poses falling in the top 25% of the score value range for all the
four scoring functions were selected for the final visual inspection. The visual inspection
process, conducted as last step, was performed using MOE 2019.10. The docking poses of
the compounds obtained from the consensus score procedure were evaluated considering
the following criteria:
• ability of a compound to overall occupy MASP-2 active site.
• number of interactions formed between the compound and the protein residues
defining the site (H-bonds, pi–pi interactions, etc.).
• coverage of different chemical scaffolds, discarding similar chemical entities.
2.1.2. Protein-Protein Docking between MASP-2 and SARS-CoV-2 N Protein and
Druggable Site Analysis
The MASP-2 crystal structure, comprising the SP, CCP1 and CCP2 domains in complex
with complement C4, was downloaded from the PDB (http://www.rcsb.org/; PDB code
4FXG [24], accessed on 30 November 2020), prepared using the MOE Protein Preparation
tools, and defined as the receptor protein in the Protein-Protein Docking tool in MOE
2019.10 [15]. SARS-CoV-2 N protein crystal structure was downloaded from the PDB (PDB
code 6M3M, [25]), prepared using the MOE Protein Preparation tools, and defined as
the ligand protein in the MOE Protein-Protein Docking tool, specifying as the interacting
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portion residues 115-123 [7]. In the receptor structure 4FXG, the portions corresponding
to the interacting regions between active MASP-2 and zymogen MASP-2 were excluded
(residues 436–441, 621–625, 564–567, 587–591, 640–645) [22,26]. Twenty output models were
generated, setting the refinement of intermediate models to none, and the refinement of
final models to medium. The 20 output models were visually inspected for the predicted
interactions between MASP-2 and the N protein interacting sequence (115–123), and for
the presence of common interaction sites/modes recurring in multiple poses. The protein-
protein docking results were combined with the prediction of potential druggable sites on
the surface of MASP-2 crystal structure 4FXG, obtained with the Site Finder tool in MOE
2019.10 [15]. The predicted presence of druggable sites on the MASP-2 surface guided
the selection of the most likely interaction model between the two proteins among the 20
docking outputs. In the selected model, the SARS-CoV-2 N protein was predicted to interact
at the junction surface between MASP-2 domains SP and CCP2. This model was saved in
mae format, preprocessed using the Schrödinger Protein Preparation Wizard by assigning
bond orders, adding hydrogens and performing a restrained energy minimization of the
added hydrogens using the OPLS_2005 force field, and then further optimized through
molecular dynamics studies.
2.1.3. Molecular Dynamics on the MASP-2-N-Protein Interaction Model
A molecular dynamics simulation was performed using the Desmond package for
Molecular Dynamic (MD) simulation [16,27], employing the OPLS_2005 force field in the
explicit solvent and the TIP3 water model. The initial coordinates for the MD simulation
were taken from the interaction model obtained from the protein-protein docking study
and the druggable site analysis. A cubic water box was used for the solvation of the
system, ensuring a buffer distance of approximately 12 Å between each box side and the
complex atoms. The system was neutralised adding four sodium counter-ions. The system
was minimised and pre-equilibrated using the default relaxation routine implemented in
Desmond. A 50 ns MD simulation was performed, during which the equation of motion
was integrated using a 2 fs time step in the NPT ensemble with temperature (300 K) and
pressure (1 atm) constant. All other parameters were set using the Desmond default values.
Data were collected every 25 ps (energy) and every 100 ps (trajectory). The simulation was
performed in triplicate, every time using a random seed as a starting point. Visualisation
of the protein–protein complex and MD trajectory analyses were carried out using Maestro
and MOE 2019.10. RMSD, secondary structure and protein–protein interactions analyses
were performed using the Simulation Event Analysis tool and the Simulation Interaction
Diagram of Desmond.
2.1.4. Docking-Based Virtual Screening at the Predicted Interaction Site between MASP-2
and SARS-CoV-2 N Protein
A second in silico screening of the virtual library of drug-repurposing compounds
was conducted at the MASP-2-N protein interaction interface (protein-protein interaction
inhibitors) identified in the final frame of the molecular dynamic simulations described
above. The interacting surface revealed on the MASP-2 protein structure was used as the
receptor, while the central portion of the SARS-CoV-2 N protein interacting sequence [7],
corresponding to residues 118–120, was included as the reference ligand to define the centre
for the docking grid in Maestro. This complex was saved in the three different formats
described above, pdb, mol2 and mae. The same docking and rescoring protocol described
in Section 2.1.1. was followed.
2.2. Complement MBL-Pathway Inhibition Assay
Selected compounds were purchased from Generon Limited and Cambridge Bio-
sciences, and dissolved in dimethyl sulfoxide (DMSO, Merck, Darmstadt, Germany).
The effect of selected compounds on the complement activation of the MBL pathway
was evaluated by the Wieslab complement MBL pathway COMPLMP320 ELISA kit (Svar
Life Sciences AB, Malmö, Skåne, Sweden), with minor modifications. The standard positive
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control of human normal serum provided in the kit was 1:101 diluted with the kit buffer,
ensuring that only the specific MBL complement pathway was activated and incubated
with 1% (v/v) of ether of the different test compounds at fixed concentrations or DMSO
(the solvent of compounds) as a control. The assay was then performed according to the
manufacturer’s specifications and as previously described [28]. Briefly, the test samples
were added to 96-well strip plates precoated with mannan and incubated for 1 h at 37 ◦C.
Heat-inactivated serum and only diluent buffer were also tested as negative and blank
controls, respectively. Each control and compound were tested in duplicate. Coated
wells were then washed with the washing buffer and incubated with a human anti-C5b-9
antibody conjugated to alkaline phosphatase (ALP) for 30 min at room temperature. After
washes, the chromogenic substrate p-NitroPhenyl Phosphate (pNPP) was added to each
well and absorbance was read at 450 nm on an ELISA plate reader (Tecan Infinite 200 PRO).
In each experiment, the absorbance of the blank control was subtracted from the absorbance
values of the other wells, and the activity of DMSO-treated serum samples without added
inhibitor was set as 100%.
2.3. Statistical Analysis
Statistical analysis was carried out using GraphPad Prism 8.0 (GraphPad Software).
Data are shown as the means ± standard deviations (SD). The dose-response curves
and IC50 values of test compounds were determined by applying a nonlinear regression
curve fitting (concentration of inhibitor versus normalised response with variable slope).
Statistical significance was calculated by two-tailed unpaired Student’s t-test.
3. Results and Discussion
3.1. Docking-Based Virtual Screening of Drug-Repurposing Compounds on MASP-2
Catalytic Site
A library of 8,736 commercially available drugs which have been licensed or tested in
clinical trials, all small molecules available from commercial sources, was screened in silico
on the catalytic site of MASP-2, in order to identify direct inhibitors of this protease. MASP-
2 plays a central role in the lectin pathway of complement activation, as its proteolytic
activity is responsible for the cleavage of the complement elements C2 into C2a (a function
shared with MASP-1), and C4 into C4b. Once cleaved, C2a and C4b are responsible for
converting the complement factor C3 into its active form C3b [23]. MASP-2 proteolytic
activity is carried out by a catalytic triad formed by His483, Asp532 and Ser633. The
structure of the MASP-2 active site is characterised by a high level of plasticity, which
is believed to support its extreme substrate specificity [23]. For our virtual screening,
the crystal structure of wild-type active MASP-2 was used (PDB ID 1Q3X) [22]. To this
structure, a reference ligand was added within the active site: the known MASP-2 peptide
inhibitor, SGMI-2, whose coordinates were taken from the 3TVJ crystal structure [23]. This
is a substrate-like, monospecific MASP-2 inhibitor, which was developed to elucidate the
specific roles of MASP-2 in the lectin-pathway of complement activation [23]. Figure 3
shows the active site of MASP-2 in the 1Q3X structure, with the central portion of the
reference ligand added.
The Glide Standard Precision docking tool (SP) [16], which uses the Glide-SP scoring
function, was employed to virtually screen the drug-repurposing database according to a
molecular docking simulation. In order to avoid any potential bias associated with the use
of a single docking program/scoring function, all docking results (docking poses) obtained
were then rescored using four different scoring functions: Glide XP [16], CHEMPLP
(PLANTS) [17], FlexX Score (Seesar) [18] and Chemgauss4 (OpenEye ScorePose) [19].
After applying a consensus score procedure (Materials and Methods 2.1.3), 1,314 molecules
were chosen. These compounds were visually inspected to assess their overall predicted
occupation of the MASP-2 active site, and to consider their potential interactions with the
amino acid residues defining this binding pocket. Following this evaluation, twenty-two
virtual hits were selected as potential MASP-2 inhibitors and purchased (Figure 4).
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in Figure 5. This molecule shows a good fitting of the target pocket, with the potential
of making multiple direct hydrogen bonds and electrostatic interactions through its two
guanidine terminal groups, with the backbone carbonyl groups of the catalytic histidine
(His483), with the side chain hydroxyl group of Ser657 and with the side chain carboxylate
groups of Glu487 and Asp627. Rescoring values for all final choices are listed in the
Supporting Information (Table S1).
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Among the 22 compounds selected and purchased for this site, nafamostat is a known
serine protease inhibitor, approved for the clinical use as an anticoagulant and to treat
acute pancreatitis, which has recently been shown to have inhibitory activity on the com-
plement system, with a positive effect for elderly patients with COVID-19-associated
pneumonia [29]. This was the best-performing compound for MASP-2 active site in our
computational study. Therefore it was kept in the final selection, also envisaging the
possibility to consider it as a potential validation tool for the use of our assay to screen for
inhibitors of the MBL pathway of complement activation. Nafamostat has also been found
to block the fusion step of viral entry of SARS-CoV-2 in in vitro studies by inhibiting the
protease activity of the host transmembrane protease serine 2 (TMPRSS2) [30]. In addi-
tion, L-skepinone has been reported to display anti-SARS-CoV-2 activity in a cell-based
assay [31], while sunitinib has been found to reduce infections by SARS-CoV, MERS-CoV
and SARS-CoV-2, partially by inhibiting the phosphorylation of AP2M1 [32].
3.2. Identification of Inhibitors of the Complement MBL Pathway
Since MASP-2 plays a critical role in the initiation of complement activation through
the MBL pathway, we tested the ability of the 22 drug-repurposing compounds to interfere
with this pathway in the Wieslab MBL complement kit. Mannan-precoated wells were
incubated with pooled normal human serum containing the test compounds at a fixed
concentration of 100 µM or DMSO as a control (Figure S1). The inhibition of the MBL
pathway activation was then detected with an alkaline phosphatase anti-C5b-9 human
antibody. Results obtained at this concentration are summarised in Figure 6.
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In this primary screening, 12 of the test compounds showed at least partial and sig-
nificant inhibition of the MBL pathway. The most potent compounds identified in this
screening were nafamostat, as partially expected, furamidine, and ceritinib, which com-
pletely abolished the complement activation of the MBL pathway at 100 µM. In addition,
also linifanib and JNJ-26481585 (quisinostat) showed the potential to interfere with this
pathway, as they both reached almost 50% inhibition at the tested concentration. While we
aim to further explore the inhibitory effect of linifanib and quisinostat in different assays,
in the first instance we selected the three most potent hits, nafamostat, furamidine and
ceritinib, to perform a dose-response analysis and calculate IC50 values in the same assay
system. Figure 7 summarises the results obtained for these three hits tested at different
concentrations again in the Wieslab MBL complement ELISA.
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In this further evaluation, nafamostat emerged as the most potent compound, with
an IC50 value of 0.057 µM (Figure 7a). Although its potential to inhibit the activation of
the complement pathway was expected, as nafamostat acts as a serine protease inhibitor
and is known to attenuate complement activation [33], the effect observed in our assay
may already represent a validation of this protocol for screening and identifying potential
inhibitors of the complement MBL pathway. In addition, as nafamostat exhibited clinical
efficacy in COVID-19 patients [29] and showed to inhibit the replication of SARS-CoV-2
in vitro studies with a very high selectivity index (i.e., >11,000) [34], the results obtained in
this assay have the potential to provide a preliminary proof of concept for our approach.
Finally, we suggest that the complement inhibitory activity previously found for nafamostat
may be related, at least in part, to a direct inhibition of the MASP-2 catalytic effect. Further
investigations are currently ongoing in our research group to assess the robustness of this
hypothesis and will be published in due course. Additional in vivo experiments are also
needed to further confirm the therapeutic potential, and safety, of the proposed approach.
Although less potent than nafamostat, furamidine and ceritinib also specifically inhibit
the MBL pathway of complement activation in a dose-dependent manner, both displaying
IC50 values in the micromolar range (Figure 7b). To the best of our knowledge, their
inhibitory effects on the complement activation cascade have not been previously reported.
Their predicted binding to MASP-2 catalytic site is shown in Figure 8.
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atoms in green) to the active site of MASP-2. The catalytic site is represented as molecular surface, 
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MASP-2 is represented as lilac ribbon, with carbon atoms for the residues shown in lilac. The ref-
erence peptide inhibitor is shown as cyan ribbon. 
Both furamidine and canertinib are associated with an optimal fitting of the MASP-2 
active site. Furamidine (Figure 8a) has the potential to engage in multiple electrostatic and 
H-bond interactions through its guanidine groups with the side chain carboxylate groups 
of Asp526 and Asp627, and with the backbone carbonyl group of Ser657. Ceritinib (Figure 
8b) is predicted to form a hydrogen bond with the side chain hydroxyl group of Ser628, a 
hydrophobic interaction with the side chain of Ala484 and a hydrogen bond with the side 
chain of Glu487, through the acidic proton of its sulfo-isopropyl group. In the case of these 
two hit molecules, further investigations are currently ongoing to assess their specific in-
hibition of MASP-2 catalytic activity, and their potential effects on related serine-prote-
ases, including both the complement system and the coagulation cascade. 
3.3. Molecular Model for the Protein-Protein Interaction between MASP-2 and Coronaviral N-
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As a parallel strategy to the identification of direct inhibitors of MASP-2 catalytic 
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action between MASP-2 and coronavirus N-proteins, and to suggest potential inhibitors 
of this interaction within our drug-repurposing library of compounds. 
Figure 8. Predicted binding of furamidine ((a), carbon atoms in grey) and ceritinib ((b), carbon atoms
in green) to the active site of MASP-2. The catalytic site is represented as molecular surface, colour-
coded according to lipophilicity (green = lipophilic, pink = hydrophilic, white = neutral). MASP-2 is
represented as lilac ribbon, ith carbon at ms for the residues shown in lilac. The reference peptide
inhibitor is shown as cyan ribbon.
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Both furamidine and canertinib are associated with an optimal fitting of the MASP-2
active site. Furamidine (Figure 8a) has the potential to engage in multiple electrostatic
and H-bond interactions through its guanidine groups with the side chain carboxylate
groups of Asp526 and Asp627, and with the backbone carbonyl group of Ser657. Ceritinib
(Figure 8b) is predicted to form a hydrogen bond with the side chain hydroxyl group of
Ser628, a hydrophobic interaction with the side chain of Ala484 and a hydrogen bond
with the side chain of Glu487, through the acidic proton of its sulfo-isopropyl group. In
the case of these two hit molecules, further investigations are currently ongoing to assess
their specific inhibition of MASP-2 catalytic activity, and their potential effects on related
serine-proteases, including both the complement system and the coagulation cascade.
3.3. Molecular Model for the Protein-Protein Interaction between MASP-2 and Coronaviral
N-Proteins
As a parallel strategy to the identification of direct inhibitors of MASP-2 catalytic activ-
ity, we carried out a series of molecular modelling simulations to elucidate the interaction
between MASP-2 and coronavirus N-proteins, and to suggest potential inhibitors of this
interaction within our drug-repurposing library of compounds.
3.3.1. Protein-Protein Docking between MASP-2 and SARS-CoV-2 N Protein
The portion responsible for the interaction with MASP-2 has recently been defined
within the structure of coronavirus N proteins [7]. It corresponds to residues 115-123 in
SARS-CoV and SARS-CoV-2 N proteins, and to residues 105-112 in MERS-CoV N protein.
Figure 9 shows the structural superimposition of these three N proteins, highlighting the
overall preservation of the three-dimensional features of the interacting sequence within
the three viruses.
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2019.10 [15], using SARS-CoV-2 N protein (PDB ID 6M3M) as a model protein for the three 
highly pathogenic coronaviruses. For this study, the crystal structure of the CCP1-CCP2-
SP portion of the active form of MASP-2 in complex with one of its substrates, C4, was 
used (PDB code 4FXG) [24]. The presence of the substrate C4 was preserved during the 
docking analysis to exclude from the docking results any possible binding mode involv-
ing the MASP-2 region where the substrate binds. In addition, the regions of MASP-2 
where the binding between zymogen form and active form of MASP-2 occurs to promote 
MASP-2 autoactivation, were also excluded from our docking study, as its interaction 
with coronavirus N proteins significantly enhances MASP-2 autoactivation [7]. Finally, as 
the CUB1-EGF-CUB2 region of MASP-2 is linked to the N-terminal portion of the CCP1 
domain, the terminal part of this subregion was also excluded from our study. From the 
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labelled for the corresponding viruses.
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The corresponding portion of MASP-2 interacting with coronaviral N proteins has
been narrowed to the CCP1-CCP2-SP C-terminal region [7], but the specific interacting
residues have yet to be identified. In order to gain insights on the binding between MASP-2
and coronaviral N proteins, a protein-protein docking study was carried out in MOE
2019.10 [15], using SARS-CoV-2 N protein (PDB ID 6M3M) as a model protein for the
three highly pathogenic coronaviruses. For this study, the crystal structure of the CCP1-
CCP2-SP portion of the active form of MASP-2 in complex with one of its substrates,
C4, was used (PDB code 4FXG) [24]. The presence of the substrate C4 was preserved
during the docking analysis to exclude from the docking results any possible binding
mode involving the MASP-2 region where the substrate binds. In addition, the regions
of MASP-2 where the binding between zymogen form and active form of MASP-2 occurs
to promote MASP-2 autoactivation, were also excluded from our docking study, as its
interaction with coronavirus N proteins significantly enhances MASP-2 autoactivation [7].
Finally, as the CUB1-EGF-CUB2 region of MASP-2 is linked to the N-terminal portion
of the CCP1 domain, the terminal part of this subregion was also excluded from our
study. From the protein-protein docking simulation, a database of 20 final models for the
interaction between the two proteins was obtained (Supporting Information, Table S2). All
models were visually inspected to evaluate potential interactions between the SARS-CoV-2
N protein interacting sequence (residues 115–123) and MASP-2, and for the presence of
common binding regions on MASP-2 recurring in multiple models, i.e., common binding
modes repeated in different docking poses. Interestingly, a common binding area, located
at the interface between MASP-2 domains CCP2 and SP, was shared by multiple models.
Next, we analyzed the surface of MASP-2 in the 4FXG crystal structure with the Site
Finder tool in MOE 2019.10 [15] to identify possible druggable sites within the region
of space available for binding to coronaviral N proteins. Figure 10 shows the structural
domains of MASP-2 in the 4FXG crystal structure, the corresponding portions excluded
from the docking simulation and all the potential druggable sites detected with the Site
Finder analysis.
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model. On top of occupying the druggable site between the CCP2 and SP domains, four 
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while Thr510 (SP) is H-bonded to Lys128, which is close in space to the known interacting 
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Interestingly, one main druggable site, highlighted with an orange circle in Figure 10, is
located at the interface between the CCP2 and SP domains in proximity to where the SARS-
CoV-2 N protein is predicted to bind in the recurring binding mode from the protein-protein
docking simulation. In this binding pose, the N protein interacting sequence (residues
115–123) is placed in close proximity to this main druggable site, suggesting its likelihood
in predicting a realistic interaction model between the two proteins. This model was used
for further structural optimization by molecular dynamics first, and then to perform the
virtual screening analysis of our drug-repurposing virtual library, to search for potential
inhibitors of this protein-protein interaction. Figure 11 shows a zoom of the predicted
interaction surface between MASP-2 and SARS-CoV-2 N protein in our docking model.
On top of occupying the druggable site between the CCP2 and SP domains, four direct
hydrogen bonds between the two proteins are present: Asn547 (SP) directly interacts with
Pro118 and Glu119, Ser546 (SP) makes a H-bond with the backbone of Gly121, while Thr510
(SP) is H-bonded to Lys128, which is close in space to the known interacting sequence
residues 115–123.




Figure 11. Protein-protein docking model between MASP-2 and SARS-CoV-2 N protein (orange 
ribbon) chosen for structural optimization by molecular dynamics: (a) overall overview of the 
binding mode, and (b) zoom on the predicted interaction site of the N protein interacting sequence 
(only residues 115-123 are shown, with carbon atoms in orange and orange ribbon, along with 
Lys128). MASP-2 domains are represented as molecular surface: CCP1 in dark blue, CCP2 in light 
blue and SP in lilac. C4 is represented as green ribbon. The druggable site at the interacting surface 
with the N protein is represented as white (hydrophobic interactions) and red (polar interactions) 
spheres. 
3.3.2. Molecular Dynamics Studies for Structural Optimization of the Interaction Model 
between MASP-2 and SARS-CoV-2 N Protein 
In order to optimize and validate the interaction model between the two proteins, a 
50 ns molecular dynamics simulation was performed on this complex using the Desmond 
software package [16,27]. This simulation was run in triplicate. The system consistently 
reached stabilization after an initial 10 ns of equilibration with the simulation converging 
around a fixed RMSD value, as shown by a small C-alpha RMSD variation for both pro-
teins analysed, MASP-2 and SARS-CoV-2 N protein (Figure S2). The geometry of the drug-
gable site on the surface of MASP-2, and the presence and nature of direct interactions 
between the two proteins, mainly focusing on those involving the N protein residues 115-
123, were monitored throughout the simulation. During the MD analyses, the N protein 
interacting sequence tended to optimize its occupation of the druggable site, maintaining 
a stable position, and to adjust its relative orientation to maximize contacts with the sur-
Figure 11. Protein-protein docking model between MASP-2 and SARS-CoV-2 N protein (orange
ribbon) chosen for structural optimization by molecular dynamics: (a) overall overview of the binding
mode, and (b) zoom on the predicted interaction site of the N protein interacting sequence (only
residues 115-123 are shown, with carbon atoms in ora ge d orange ribbon, along with Lys128).
MASP-2 domains are represented as mol cular surface: CCP1 in dark blue, CCP2 in light blue and
SP in lilac. C4 is represented as green ribbon. The druggable site at the interacting surface with the N
protein is represented as white (hydrophobic interactions) and red (polar interactions) spheres.
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3.3.2. Molecular Dynamics Studies for Structural Optimization of the Interaction Model
between MASP-2 and SARS-CoV-2 N Protein
In order to optimize and validate the interaction model between the two proteins, a
50 ns molecular dynamics simulation was performed on this complex using the Desmond
software package [16,27]. This simulation was run in triplicate. The system consistently
reached stabilization after an initial 10 ns of equilibration with the simulation converging
around a fixed RMSD value, as shown by a small C-alpha RMSD variation for both proteins
analysed, MASP-2 and SARS-CoV-2 N protein (Figure S2). The geometry of the druggable
site on the surface of MASP-2, and the presence and nature of direct interactions between
the two proteins, mainly focusing on those involving the N protein residues 115–123, were
monitored throughout the simulation. During the MD analyses, the N protein interacting
sequence tended to optimize its occupation of the druggable site, maintaining a stable
position, and to adjust its relative orientation to maximize contacts with the surrounding
MASP-2 residues. The presence of SARS-CoV-2 N protein also induced a structural and
spatial optimization of the MASP-2 residues defining the druggable site, which became
more definite towards the end of all three simulations.
Distinct direct contacts between the N protein interacting sequence and residues of
MASP-2, mainly hydrogen bonds, were consistently present during the entire MD simula-
tion, providing useful insights for searching for inhibitors. In particular, following analysis
of the simulations with the Simulation Interaction Diagram function of Desmond [27], the
MASP-2 residues Arg376, Tyr401, His508, Asn545, Ser546 and Asn547 were involved in
hydrogen bonds with the interacting sequence of SARS-CoV-2 N protein for a relevant
fraction of the simulation time (Supporting Information, Figure S3). In addition, MASP-2
residues involved in likely hydrophobic interactions with the N protein interacting se-
quence were also revealed: Phe400, Tyr401 and Val543 (Supporting Information, Figure S3).
Representative individual frames of the triplicate simulation were systematically visually
inspected for the presence of additional contacts between MASP-2 and the N protein inter-
acting sequence using MOE 2019.10 [15]. Findings from this visual inspection are reported
in the Supporting Information (Table S3).
The final optimized complex after molecular dynamics, with a zoom on the druggable
site located at the interaction surface between MASP-2 and the N protein interacting
sequence, is shown in Figure 12.
3.3.3. Virtual Screening on the Predicted Interaction Site between MASP-2 and
SARS-CoV-2 N Protein
A drug-repurposing library of 8736 licensed drugs and clinical agents was analyzed
according to a second virtual screening with the aim of identifying small molecules able
to bind at the interaction site defined by the SARS-CoV-2 N protein interacting sequence
on the MASP-2 surface in the final, optimized complex model after MD. Following the
same approach described above for the MASP-2 active site (3.1), after consensus scoring
a total of 851 molecules were chosen as potential disruptors of the interaction between
SARS-CoV-2 N protein and MASP-2. These compounds were visually inspected for their
overall occupation of the target druggable site on MASP-2 where the N-protein interacting
sequence is predicted to bind. After visual inspection, twenty-four virtual hits were selected
and purchased (Figure 13).
All these molecules showed an optimal overall occupation of the druggable site in
our model, with the potential of forming hydrogen bonds and hydrophobic interactions
with different residues of MASP-2, as exemplified in Figure 14, by the predicted binding
of DB11867. On top of showing a good fitting of the site, this compound is also predicted
to make a direct hydrogen bond with the side chain hydroxyl group of Tyr401 (CCP2).
By interacting with this portion of MASP-2, these compounds could potentially prevent
coronavirus N proteins from binding, thus interfering specifically with the virus-induced
hyperactivation of MASP-2. Rescoring values for all final choices are listed in the Support-
ing Information (Table S4).
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Among the 24 drug-repurposing molecules selected, some agents have already been
proposed as candidates for COVID-19 repurposing. Assumption of folic acid has been
observed to protect pregnant women from SARS-CoV-2 infection, with contrasting evidence
suggesting that it may either inhibit the furin protease, needed by the virus to enter the
host cell, or the protease 3CLpro, essential for viral replication [37]. As a small-molecule
antiviral agent, tegobuvir has been evaluated in clinical trials for COVID-19 [38], while
bisoxatin (DB09219) has been suggested as a potential inhibitor of SARS-CoV-2 spike
protein following a computational approach [39]. Amodiaquine has been found to inhibit
SARS-CoV-2 replication in vitro [40], ketanserin has been suggested as a potential additive
drug to improve the ventilation/perfusion mismatch in patients with COVID-19 [41] and,
finally, the anti-HIV drug raltegravir has been proposed as a potential 3CLpro inhibitor
following a computational approach [42].
We are currently working towards the development of an ELISA assay to first confirm
the interaction between the MASP-2 catalytic domain and SARS-CoV-2 N protein, and then
to evaluate the twenty-four selected candidates for their inhibition of this interaction.
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Figure 12. Predicted binding mode betwe n MASP-2 C-terminal region and SARS-CoV-2 N protein
(orange ribbon) after MD simulation: overview of the final interacting complex (a) and zoom on the
interaction site defined by the interacting sequence of SARS-CoV-2 N-protein (b). MASP-2 domains
are represented as molecular surface: CCP1 in dark blue, CCP2 in light blue and SP in lilac. The
druggable site at the interacting surface with the N protein interacting sequence is represented as
white (hydrophobic interactions) and red (polar interactions) spheres. Carbon atoms of the N protein
residues are in orange.
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(hydrophobic interactions) and red (polar interactions) spheres. SARS-CoV-2 N protein is represented
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4. Conclusions
MASP-2 represents an important target for the development of therapeutic measures
to interfere with the severe consequences of infections with highly pathogenic coron-
aviruses SARS-CoV, MERS-CoV and SARS-CoV-2. By directly interacting with MASP-2
through their N proteins, these viruses induce MASP-2 hyperactivation, leading to severe
lung injury in patients. In this work, we followed two parallel strategies to interfere with
the MASP-2 hyperactivation induced by these viruses. First, we performed a docking-
based virtual screening of a virtual library of 8,736 licensed drugs and clinical agents
on the catalytic site of MASP-2, searching for direct inhibitors of its proteolytic activity.
For this in silico study, we selected and purchased a total of 22 drug-repurposing candi-
dates. These molecules were preliminarily evaluated in an in vitro assay to determine
their potential interference with the MBL pathway of complement activation: different
candidates were found to inhibit this pathway. In particular, we observed a potent effect
for nafamostat, which had been at least partially described previously, and an interesting
effect for furamidine and ceritinib, which both displayed IC50 values in the micromolar
range. Complement inhibitory activity for these two licensed drugs has not been de-
scribed previously. Currently, we are evaluating all our chosen candidates in further assay
systems for their direct and selective inhibition of MASP-2 catalytic activity. However,
it should be noted that ceritinib has shown to clinically induce interstitial lung disease,
limiting its potential use against COVID-19 [43]. In parallel, we also performed a series of
protein-protein docking studies and molecular dynamics simulations, to investigate the
interaction between coronavirus N proteins and MASP-2, and to propose this interaction
as a target for the identification of specific anti-coronavirus agents. While the amino acid
sequence responsible for the interaction has been identified for coronaviral N proteins,
information on the interacting portion of MASP-2 has yet to be reported. Nonetheless,
the MASP-2 interacting portion has been previously narrowed down to the CCP1, CCP2
and SP domains. In this work, we revealed a plausible interaction site on the surface
of MASP-2, where the interacting sequence of coronavirus N proteins is likely to bind.
Our model provides a useful tool for the identification or the design of specific inhibitors
of this interaction for therapeutic purposes. With the aim to identify drug-repurposing
candidates able to prevent this protein-protein interaction, we used our model to perform
a second, independent virtual screening of the drug-repurposing library. We identified 24
promising candidates as potential inhibitors of this interaction, and are currently setting up
multiple assays for their biochemical function evaluation. Overall, we highlight here the
potential of our approach to pave the way for the development of a support therapeutic
measure for present and future-emerging coronaviral infections, to decrease the severe
consequences and high mortality rates of these viral diseases. The potent activity observed
for nafamostat in our preliminary assay provides an initial proof of concept for our strategy.
In addition, our promising findings for nafamostat, furamidine and ceritinib also suggest
the potential of successfully finding additional, novel therapeutic agents by extending our
in silico methodology to the evaluation of much bigger libraries of drug-like compounds.
Finally, these initial data represent an encouraging confirmation of how computer-aided
methods can guide the identification of biologically active compounds, further supporting
the likelihood of identifying effective, specific protein-protein interaction inhibitors of
MASP-2 interaction with coronavirus N proteins.
Supplementary Materials: The following are available online at https://www.mdpi.com/1999-491
5/13/2/312/s1, Table S1: Rescoring values for drug-repurposing compounds chosen for MASP-2
active site, Table S2: Protein-protein docking results (models) between MASP-2 and SARS-CoV-
2 N protein, Figure S1: Effect of serum heat-inactivation and DMSO on the MBL complement
pathway activity, Figure S2: RMSD values for the alpha-carbon atoms of the two proteins during MD
simulations, Figure S3: Direct contacts between MASP-2 and the interacting sequence of SARS-CoV-2
N protein during the MD simulation, Table S3: Direct contacts between MASP-2 and SARS-CoV-2 N
proteins in discrete MD frames, and MASP-2 residues defining the interaction site between the two
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proteins, Table S4: Rescoring values for drug-repurposing compounds chosen for the interaction site
between MASP-2 and SARS-CoV-2 N protein.
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